Abivax

Until approval and launch, revenue and FCF are inherently unpredictable. The Phase 3 induction wins de‑risk efficacy at 8 weeks and pooled safety, but the pivotal 44‑week maintenance outcome remains pending in late Q2 2026 and will determine the reliability of long‑term control and real‑world persistency.

Post‑approval predictability would benefit from oral convenience and multi‑pathway immunoregulation, yet class competition, access hurdles and potential label nuances can introduce variability. Geographic diversification will follow sequential approvals, limiting single‑country exposure over time.

Score reflects pre‑revenue uncertainty with a potential step‑change upward on positive maintenance data.